Table 3.
Risk factors for positive seroconversion of HBsAg in HBsAg-negative patients detected during diagnosis of hematological malignancy
| Positive Sero- conversion (n = 41) |
No conversion (n = 1635) |
Univariate P value |
Multivariate P value | Odds ratio (95% CI) |
|
|---|---|---|---|---|---|
| Age | 0.174 | NA | |||
| ≧65 years | 12 | 466 | |||
| < 65 years | 29 | 1169 | |||
| Gender | 0.737 | NA | |||
| Men | 22 | 866 | |||
| Women | 19 | 769 | |||
| Hematological malignancy | 0.038 | 0.084 | NA | ||
| AML | 5 | 526 | |||
| ALL | 7 | 140 | |||
| Lymphoma | 24 | 603 | |||
| CML/MPN | 0 | 54 | |||
| CLL | 1 | 21 | |||
| Myeloma | 3 | 163 | |||
| MDS / AA | 1 | 128 | |||
| Diabetes mellitus | 0.040 | 0.005 | 0.218(0.076–0.629) | ||
| Yes | 10 | 233 | |||
| No | 31 | 1402 | |||
| Allogeneic transplantation | 0.116 | 0.013 | 0.182(0.047–0.701) | ||
| Yes | 15 | 365 | |||
| No | 26 | 1270 | |||
| Liver cirrhosis | <0.001 | <0.001 | 0.002(0.000–0.047) | ||
| Yes | 2 | 8 | |||
| No | 39 | 1627 | |||
| Hepatocellular carcinoma | 0.748 | NA | |||
| Yes | 0 | 5 | |||
| No | 41 | 1630 | |||
| Hepatitis C | 0.216 | NA | |||
| Yes | 0 | 65 | |||
| No | 41 | 1570 | |||
| Negative Anti-HBs Antibodya | 0.237 | NA | |||
| Yes | 10 | 304 | |||
| No | 24 | 1157 | |||
| Low Anti-HBs Antibody a | 0.002 | 0.016 | 0.020(0.001–0.480) | ||
| Yes | 30 | 915 | |||
| No | 4 | 546 | |||
| Positive Anti-HBc Antibodyb | 0.005 | 0.013 | 0.070(0.009–0.571) | ||
| Yes | 18 | 567 | |||
| No | 1 | 263 |
NA not available, a Anti-HBs Antibody checked, (n = 1495), Low Anti-HBs Antibody <100mIU/mL, b Anti-HBc Antibody checked (n = 849), AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML/MPN chronic myeloid leukemia/myeloproliferative neoplasm, CLL chronic lymphocytic leukemia, MM myeloma, MDS/AA myelodysplastic syndrome/aplastic anemia